Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spine Society Adopts Stricter Conflict Disclosure Policy

This article was originally published in The Gray Sheet

Executive Summary

Members of the North American Spine Society and all practitioners who present at NASS meetings, publish in its journals, or serve on its committees will for the first time need to disclose dollar amounts of financial ties to device companies

You may also be interested in...



Clarification

A story in the Feb. 2 issue of "The Gray Sheet" (1p. 8) mentions NuVasive, TranS1 and Alphatec Spine as examples of spine device manufacturers. The story does not intend to suggest that the firms are under investigation by the government

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

Topics

UsernamePublicRestriction

Register

MT027065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel